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In the original DECS study [3], dexamethasone did not 
reduce the incidence of postoperative AF, suggesting that 
a single dose of dexamethasone cannot effectively ame-
liorate atrial inflammation, which is one of the presumed 
arrhythmogenic mechanisms. In line with that previous 
observation in the main DECS study, the present substudy 
shows that dexamethasone is not associated with preserva-
tion of atrial function at the very end of the operation.
We again commend the investigators for having perfor-
med such extensive TEE analyses. We understand that col-
lecting data immediately after surgery was most appropriate 
considering the complex logistics and limited acceptance of 
TEE in the awake patient. On the other hand, atrial inflam-
mation may not be at its peak right after surgery and there-
fore the investigators may have missed the beneficial effects 
of dexamethasone on atrial function. This notion is fed by 
the fact that postoperative AF reaches its highest incidence 
on day two after cardiac surgery [4].
Comparing preoperative and postoperative left atrial 
(LA) function within the dexamethasone and placebo 
groups (rather than the presented comparison between dexa-
methasone and placebo before and after surgery) suggests 
that the LA total emptying fraction is stable in the placebo 
group, while it seems to decrease in the dexamethasone 
group. Whilst correction of the LA function parameters for 
fluid status may appear explanatory one cannot exclude 
an early unexpected deleterious effect of dexamethasone 
potentially precluding a net positive effect during the next 
few days after surgery. Future studies on postoperative atrial 
inflammation may shed more light on these notions.
The present study shows the feasibility of assessing peri-
operative atrial function using TEE. However, it also illus-
trates the limitations of fitting methodology to standard care 
which precluded observing atrial inflammation when it—
expectedly—was at its peak. To paraphrase the present Dean 
Atrial fibrillation (AF) occurs frequently after cardiac sur-
gery and is mostly self-limiting. It relates to direct surgical 
effects on the atria, atrial ischaemia during surgery, adrener-
gic activation and a general state of inflammation. Although 
most postoperative AF is transient, it may lead to a prolonged 
hospital stay and increased mortality [1]. Treatment strate-
gies include the use of beta blockers, several antiarrhythmic 
drugs such as propafenone, sotalol and amiodarone, antioxi-
dants to reduce ischaemia-reperfusion damage, angiotensin 
inhibition and anti-inflammatory medication such as N-ace-
tylcysteine, naproxen, colchicine and glucocorticosteroids.
In this edition of the Netherlands Heart Journal, Jacob 
et al. [2] report a substudy of the DECS study [3], which 
aims to describe the influence of a single high-dose infusion 
of the glucocorticoid dexamethasone during cardiac surgery 
on the perioperative function of the left atrium and the deve-
lopment of postoperative AF.
The authors have put much effort into the sophisticated 
analysis of transoesophageal echocardiography recordings 
(TEE). We commend the investigators for their focus on 
atrial function rather than atrial size only, especially since 
atrial function may better reflect atrial pathophysiology 
than merely looking at atrial anatomy. Their methodology 
should be followed when evaluating atrial performance in 
order to understand atrial remodelling processes much more 
efficiently.
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and Vice Chairman of the Board of the University Medical 
Centre Utrecht, it is time for a ‘transition in science’ [5]. 
Among others, this may be taken by clinical scientists as 
a call for always creating the most optimal methodologies 
whilst respecting clinical routines. This certainly will con-
tribute to producing high-quality papers with impact, which 
can be used to guide important clinical decisions and thus 
improve the quality and length of patients’ lives [5].
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